Tebentafusp plus roginolisib for metastatic uveal melanoma to support T-cell balance

TRIUMPH - Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis

This trial tests whether adding roginolisib to ongoing tebentafusp helps maintain T‑cell balance in adults with HLA‑A*02:01 metastatic uveal melanoma.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: St Vincent's Hospital, Sydney (Academic / other)
• Drugs / interventions: radiation, prednisone
• Locations: 2 sites (Sydney, New South Wales and 1 other locations)
• Trial ID: NCT07203391 on ClinicalTrials.gov

What this trial studies

This Phase 1 program adds the PI3Kδ inhibitor roginolisib to standard tebentafusp treatment beginning in cycle 4 for adults with unresectable or metastatic uveal melanoma who are HLA‑A*02:01 positive and have ECOG 0–1. Participants must be receiving first‑line tebentafusp and have any tebentafusp‑related toxicities resolved to grade ≤1. The study’s primary focus is safety and tolerability while measuring effects on T‑cell homeostasis, with exploratory biomarker and preliminary efficacy endpoints. Treatment is being delivered at St Vincent’s Hospital (Sydney) and The Alfred (Melbourne) with close monitoring for immune and hematologic safety.

Who should consider this trial

Good fit: Adults (≥18) with HLA‑A*02:01 positive, unresectable or metastatic uveal melanoma who are on first‑line tebentafusp, have ECOG 0–1, and have tebentafusp toxicities resolved to grade ≤1.

Not a fit: Patients who are HLA‑A*02:01 negative, not receiving tebentafusp, pregnant or lactating, or with poor performance status or unresolved high‑grade tebentafusp toxicity are unlikely to benefit.

Why it matters

Potential benefit: If successful, the combination could prolong functional T‑cell responses and potentially improve disease control in metastatic uveal melanoma.

How similar studies have performed: Tebentafusp has shown survival benefit in metastatic uveal melanoma, while combining it with PI3Kδ inhibitors like roginolisib is a novel strategy supported by preclinical rationale but with limited clinical data so far.

Eligibility criteria

Inclusion Criteria:

1. Male or female participants must be aged 18 years or over at the time, to be eligible to participate in this study.
2. Histologically or cytologically confirmed metastatic UM or unresectable UM patients
3. HLA-A\*02:01 positive
4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
5. Currently undergoing first-line treatment for mUM with tebentafusp
6. Tebentafusp related toxicity, including cytokine release syndrome that has resolved to grade ≤ 1 as per CTCAE v5.0.
7. Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control (eg double barrier) from the trial screening date until 6 months after the final dose of the program intervention; cessation of birth control after this point shall be discussed with a responsible physician.
8. Pregnant or lactating women are prohibited from enrolling on this program.
9. Male participants are not allowed to donate sperm from the time of enrolment until 6 months post- administration of program interventions.

Exclusion Criteria:

1. Presence of untreated or symptomatic central nervous system (CNS) metastases, leptomeningeal disease, or cord compression. NOTE: Participants with treated CNS lesions may enroll provided all of the following apply:

   1. Treated CNS lesions must be radiographically stable for ≥ 4 weeks after intervention (surgery and/or radiation).
   2. Participants must be neurologically stable off systemic corticosteroids for at least 2 weeks prior to trial entry
2. Ongoing Grade 2 or greater treatment related toxicity due to tebentafusp
3. Prior treatment with a PI3Kδ inhibitor
4. Prior Grade 4 cytokine release syndrome related to Tebentafusp
5. Systemic treatment with steroids or any other immunosuppressive drug use within 2 weeks of the planned first dose of program intervention, with the following exceptions:

   1. Treatment for well-controlled and asymptomatic adrenal insufficiency is permitted, but replacement dosing is limited to prednisone ≤ 10 mg daily or the equivalent.
   2. Local or topical steroid therapies (eg, optic, ophthalmic, intra- articular, or inhaled medications) are acceptable.
   3. Premedication for allergy to contrast reagent.
6. Any relevant medical condition, which in the opinion of the treating physician, would prevent the participant enrolling into the Program due to concerns related to safety, compliance with procedures, or interpretation of program results.
7. Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications.
8. Chronic viral infections as indicated below. NOTE: Testing for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) status prior to enrollment is not necessary unless clinically indicated.
9. Known HIV infection unless all of the following are applicable:

   1. Receiving an approved, stable, effective combination antiretroviral therapy regimen for ≥3 months prior to the planned first study intervention
   2. CD4 T-cell count \>350 cells/µl
   3. CD4 T-cell nadir (lowest historical count) \< 350 cells/µl
   4. Viral load confirmed as \<50 copies/ml during Screening.
10. Known HBV infection, unless on stable anti-viral therapy for \> 4 weeks prior to the planned first dose of program intervention and viral load confirmed as undetectable during Screening.
11. Known HCV infection, unless the participant has received curative treatment, and viral load was confirmed as undetectable during Screening.
12. Participant with an out-of-range Screening laboratory values defined as shown below. NOTE: Hematology evaluations must be performed ≥ 7 days from any blood or blood product transfusion and ≥ 14 days from any dose of hematologic growth factor.

    1. Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) \< 30 mL/minute.
    2. Total bilirubin \> 1.5 × ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin \> 3.0 × ULN or direct bilirubin \> 1.5 × ULN.
    3. Alanine aminotransferase \> 5 × ULN in the presence of liver metastases; \> 3 X ULN if not
    4. Aspartate aminotransferase \> 5 × ULN in the presence of liver metastases ; \> 3 X ULN if not
    5. Platelet count \< 75 × 109/L
    6. Hemoglobin \< 9 g/dL
13. Clinically significant cardiac disease or impaired cardiac function, including any of the following:

    1. Congestive heart failure (New York Heart Association Class ≥ 3)
    2. QTcF\>470msec at baseline
    3. Uncontrolled hypertension defined as systolic blood pressure \[BP\] \> 160 mmHg or diastolic BP \> 110 mmHg with the following requirements:
    4. If initial measurement is elevated, additional assessments should be taken where each assessment is the mean value of 3 measurements taken at least 5 minutes apart.
    5. Eligibility is based on the average of at least 2 assessments taken at least 1 hour apart.
    6. Acute myocardial infarction or unstable angina pectoris \< 6 months prior to the planned first dose of program intervention.

Where this trial is running

Sydney, New South Wales and 1 other locations

• St Vincents Hospital — Sydney, New South Wales, Australia (Recruiting)
• Alfred Hospital — Melbourne, Victoria, Australia (Not_yet_recruiting)

Study contacts

• Principal investigator: Anthony Joshua, MBBS PhD FRACP — St Vinents Hospital sydney

Conditions Uveal Melanoma, Metastatic; tebentafusp; Roginolisib